Completed PHASE3 INTERVENTIONAL 1-arm NCT00512135

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

A Prospective, Open-label, Multicenter, Repeat-dose Trial to Investigate the Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

Sponsor: Merz Pharmaceuticals GmbH

Conditions Glabellar Lines

Interventions IncobotulinumtoxinA (Xeomin) (20 units)

Updated 8 times since 2017 Last updated: Mar 8, 2021 Started: Jun 18, 2007 Primary completion: Dec 28, 2009 Completion: Dec 28, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00512135, this PHASE3 trial focuses on Glabellar Lines and remains completed. Sponsored by Merz Pharmaceuticals GmbH, it has been updated 8 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — May 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merz Pharmaceuticals GmbH

Data source: Merz Pharmaceuticals GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aventura, United States , Berlin, Germany , Carmel, United States , Chestnut Hill, United States , Coral Gables, United States , Darmstadt, Germany , Dresden, Germany , Englewood, United States , Frankfurt am Main, Germany , Hamburg, Germany and 14 more locations